CLK4 and familial pancreatic carcinoma: Researchers established a computational model integrating CLK4 inhibitor pharmacology and identified the novel specific CLK4 inhibitor compound 150441, which significantly inhibits pancreatic cancer cell growth and survival in cell models [97].